Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas
December 01, 1998
The article by Dr. McLaughlin and coauthors provides both a useful summary of the clinical trials involving rituximab (IDEC C2B8 [Rituxan]) and a practical guide for its administration. Their review summarizes the most recent clinical results with this monoclonal antibody, which have just been published in the Journal of Clinical Oncology. The review also includes a section on the potential mechanism of action of rituximab. Several areas merit comment.